Additionally, numerous very well established adverse prognostic markers, such as U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, misplaced their damaging effect in people handled with VO. The only issue that remained predictive of a shorter development-cost-free survival in this cohort of individuals was TP53 aberrations.112 At last, the alternat